{"id":124216,"date":"2026-09-02T08:39:27","date_gmt":"2026-09-02T08:39:27","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/124216\/"},"modified":"2026-09-02T08:39:27","modified_gmt":"2026-09-02T08:39:27","slug":"roche-reloads-b-cell-strategy-with-1-53b-simcere-deal","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/124216\/","title":{"rendered":"Roche reloads B-cell strategy with $1.53B Simcere deal"},"content":{"rendered":"<p class=\"isSelectedEnd\">Why it matters: The Swiss pharma is doubling down on therapies that achieve deeper B-cell depletion, an increasingly competitive strategy spanning blood cancers and autoimmune diseases \u2014 just weeks after Roche abandoned another T-cell engager it had been testing in lupus.<\/p>\n<p class=\"isSelectedEnd\">Zoom in: Roche receives exclusive worldwide rights to develop, manufacture and commercialize SIM0660. Simcere is eligible for development, regulatory and commercial milestones, taking total payments to $1.53 billion, plus tiered royalties reaching double-digit percentages.<\/p>\n<p class=\"isSelectedEnd\">How it works: The antibody simultaneously targets CD79a and CD19 on B cells while engaging CD3 on T cells, redirecting the immune cells to kill the targeted B cells.<\/p>\n<p>The idea behind hitting two B-cell markers is to broaden the population of cells that can be eliminated, potentially including cells that escape therapies targeting a single antigen. Simcere also designed the molecule to limit cytokine release, a major safety concern with T-cell engagers.<\/p>\n<p class=\"isSelectedEnd\">Backstory: Roche already has considerable experience targeting B cells. Its portfolio includes anti-CD20 antibodies Gazyva and Rituxan\/MabThera, as well as approved CD20xCD3 T-cell engagers Lunsumio and Columvi for B-cell cancers.<\/p>\n<p>The company is also pushing B-cell depletion deeper into autoimmune disease. Gazyva is under regulatory review for systemic lupus erythematosus after a positive Phase 3 trial, while Roche has identified B-cell-depleting bispecific antibodies and allogeneic CAR-T therapies among its immunology pipeline priorities.<\/p>\n<p class=\"isSelectedEnd\">Yes, but: Roche recently learned how difficult translating the T-cell engager approach into autoimmune disease can be. In July, it discontinued RG6382, a CD19xCD3 bispecific being studied in Phase 1 lupus patients, after concluding the molecule lacked the characteristics needed to advance in that indication.<\/p>\n<p>SIM0660 therefore gives Roche another \u2014 potentially broader \u2014 way of pursuing deep B-cell depletion. But the companies have not disclosed which diseases Roche plans to test first, and the asset has yet to enter human trials.<\/p>\n<p class=\"isSelectedEnd\">Big picture: The agreement is also the latest validation of Simcere\u2019s growing role as a source of assets for Western pharma. The Chinese group says it has now completed six out-licensing transactions carrying more than $6.1 billion in potential payments. Those deals include:<\/p>\n<p>AbbVie\u2019s $1.05 billion pact for the Phase 1 trispecific T-cell engager SIM0500<br \/>\nNextCure\u2019s $745 million agreement for ex-China rights to the Phase 1 antibody-drug conjugate SIM0505<br \/>\nIpsen\u2019s $1.06 billion deal for the preclinical LRRC15-targeting ADC SIM0613.<br \/>\n<a href=\"https:\/\/european-biotechnology.com\/latest-news\/china-again-boehringer-turns-to-shanghai-for-ibd-bispecific\/\" rel=\"nofollow noopener\" target=\"_blank\"> Boehringer Ingelheim\u2019s \u20ac1.05 billion deal<\/a> for rights outside Greater China to Simcere\u2019s preclinical TL1A\/IL-23 bispecific SIM0709 for inflammatory bowel disease.<\/p>\n<p>Bottom line: Roche is not giving up on deeper B-cell depletion after its lupus setback. Instead, it is paying for another shot, this time with two B-cell targets instead of one.<\/p>\n","protected":false},"excerpt":{"rendered":"Why it matters: The Swiss pharma is doubling down on therapies that achieve deeper B-cell depletion, an increasingly&hellip;\n","protected":false},"author":2,"featured_media":124217,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[14272,134],"class_list":["post-124216","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-licensing","tag-roche"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117200549689879016","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/124216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=124216"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/124216\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/124217"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=124216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=124216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=124216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}